Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610

Event to be held on December 6, 2023 will focus on preventing basal cell carcinomas associated with Gorlin syndrome with a discussion of the disease burden, SGT-610 and the upcoming Phase 3 trial NESS ZIONA, Israel, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL) (“Sol-Gel”), a dermatology company leveraging innovative approaches to develop pioneering treatments for patients with severe skin conditions, and with two approved large-category dermatology products, TWYNEO

Related Keywords

Oakland ,California ,United States ,United Kingdom ,University Of California San Francisco ,Jerusalem ,Israel General ,Israel ,San Francisco ,American ,Israeli ,Ervin Epstein ,Irina Koffler ,Ervin Epstein Jr ,Gilad Mamlok ,Julie Breneiser ,Nasdaq ,National Institutes Of Health ,Founder Of Pellepharm Inc ,Company Annual Report On Form ,Gorlin Syndrome Alliance ,Hebrew University Of Jerusalem ,Peptor Ltd ,University Of California ,Amd Co ,Exchange Commission ,Pellepharm Inc ,Society For Investigative Dermatology ,Gel Technologies Ltd ,American Dermatological Association ,Research Dermatologist ,Oxford University ,Phd Co ,Gel Technologies ,Executive Director ,Orphan Drug Designation ,Breakthrough Designation ,Chief Executive Officer ,Sol Gel Therapeutics ,Board President ,Physician Assistant ,National Institutes ,Congressionally Directed Medical Research ,Medical Advisor ,Clinical Professor ,American Dermatological ,New England Journal ,Alon Seri Levy ,Hebrew University ,Gorlin Syndrome ,Orphan Drug ,Private Securities Litigation Reform Act ,Annual Report ,Basal Cell Carcinomas ,Rvin Epstein Jr ,Sol Gel ,Dermatology Products ,Genetic Disorder ,